FHLKX
Price
$10.31
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
ONCFX
Price
$12.89
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
Ad is loading...

FHLKX vs ONCFX

Header iconFHLKX vs ONCFX Comparison
Open Charts FHLKX vs ONCFXBanner chart's image
Fidelity Health Savings K
Price$10.31
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
JPMorgan Investor Conservative Growth I
Price$12.89
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
FHLKX vs ONCFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FHLKX vs. ONCFX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FHLKX is a StrongBuy and ONCFX is a Hold.

FUNDAMENTALS
Fundamentals
ONCFX has more cash in the bank: 3.97B vs. FHLKX (59.8M). ONCFX (2.99) and FHLKX (2.95) have matching dividends . FHLKX was incepted earlier than ONCFX: FHLKX (5 years) vs ONCFX (28 years). FHLKX is a more actively managed with annual turnover of: 46.00 vs. ONCFX (5.00). FHLKX has a lower initial minimum investment than ONCFX: FHLKX (0) vs ONCFX (1000000). ONCFX (13.47) and FHLKX (13.22) have marching annual gain over last year.
FHLKXONCFXFHLKX / ONCFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years28 years-
Gain YTD7.2288.13189%
Front LoadN/AN/A-
Min. Initial Investment01000000-
Min. Initial Investment IRAN/A1000000-
Net Assets59.8M3.97B2%
Annual Yield % from dividends2.952.9999%
Returns for 1 year13.2213.4798%
Returns for 3 years-1.04-1.1988%
Returns for 5 yearsN/A13.47-
Returns for 10 yearsN/A23.61-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETADX20.090.03
+0.15%
Eventide Dividend Growth A
ABMIX25.58-0.02
-0.08%
AMG River Road Mid Cap Value I
VBIAX50.67-0.04
-0.08%
Vanguard Balanced Index Adm
FGRTX26.39-0.07
-0.26%
Fidelity Mega Cap Stock
BRKRX13.95-0.10
-0.71%
MFS Blended Research Em Mkts Eq R1